Didn't the chemgenex trial use a single arm omapro design in imatinib resistant patients even though Sprycel (approved mid '06) and perhaps Tasigna (approved late '07) were both approved and available?
No, that's not what i'm saying. I expect an open label study.
I don't think the fda will be curious about Omapro+ariad and I don't think the combo will lead to cures. That's certainly a very speculative trial idea you have and would take many many years to accrue and run.
Like i suggested we can just wait and see what happens with the Omapro nda and the ariad pivotal trial. The trial design should be clarified by the middle of next year.
News 
Market Data 
Discover 
AI
